Tenofovir Alafenamide Switch Therapy in Chronic Hepatitis B
Recruiting
Observational Study
Patient Satisfaction
Drug Adherence
Efficacy, Self
Safety Issues
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 20 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 60 (estimated)
- Sponsor
- Taichung Veterans General Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Chronic hepatitis B (CHB) patients may be unsatisfied to entecavir (ETV) therapy due to the inconvenience in drug taking, i.e., fasting for more than 2 hours and/or dose adjustment according to estimated glomerular filtration rate (eGFR). However, tenofovir alafenamide (TAF) has been approved to be highly effective and safe in patients with CHB, and is convenient in drug taking, i.e., once daily r…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. At least 20 years of age
2. Detectable serum HBsAg
3. Chronic HBV infection under ETV therapy
4. ETV users who are unsatisfied with the efficacy and/or feel inconvenient of ETV therapy
5. No contraindications for TAF switch therapy
6. HBV antiviral period expectancy for at le…
Contacts